90101-16-9

Droxicam is an orally-active prodrug of piroxicam useful in the treatment of spinal osteoarthritis. Although it has a pharmacological profile comparable to piroxicam, droxicam's experimental ulcerogenic effect is ten times less. In animal studies droxicam is also reported to have analgesic and antipyretic activities, with no cardiovascular or respiratory effects.

Esteve (Spain)

ChEBI: An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respe tively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.

Ombolan

Droxicam is authorized to be marketed in many European countries. Although droxicam is metabolized to piroxicam, it is considered that the risk of hepatic damage differs from that shown by other NSAIDs products, including piroxicam.